Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor
Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor
Modulation of the GIP System in Patients With Acromegaly Due to a Pituitary adenoma
Aim: To determine the importance of the GIP system in patients with acromegaly who has
 paradoxical growth hormone secretion during an oral glucose tolerance test (OGTT) using a GIP
 antagonist (GIP-A).

 Thirty participants (age 18-75 years) with normal kidney and liver parameters and hemoglobin
 levels will be included in a placebo-controlled cross-over study. The study consists of two
 study days with concomitant infusions of A) GIP-A or B) saline (placebo).
Inclusion Criteria:

 -  Patients under clinical investigation of acromegaly disease with normal kidney
 function, liver function and hemoglobin levels.

 Exclusion Criteria:

 -  Medication for acromegaly, adenectomy, liver disease, uncontrolled anemia, severe
 heart disease, uncontrolled high blood pressure (>170/100 mmHg), current pregnancy